Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00430846 | Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies | PHASE1 | COMPLETED | 45 | — | — | Nov 1, 2006 | Jul 1, 2009 | Dec 18, 2014 | 4 | United States |
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| SGN-35 | DRUG | Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg |
Inclusion Criteria: * Patients must have histologically confirmed CD30-positive hematologic malignancy. * Patients with HL must have failed systemic chemotherapy either as induction therapy for advanced stage disease or salvage therapy after initial radiotherapy for early stage disease and were ine...